hotspot -WSS

hotspot

author：comprehensive 2025-09-28 23:49:03 - browse：91384

AstraZeneca said Friday it will buy up a group of early-stage gene therapies from Pfizer, bucking a trend of drugmakers axing programs and exiting a field that had once captured the imagination — and checkbooks — of many pharmaceutical executives.

AstraZeneca will pay Pfizer up to $1 billion plus royalties for the portfolio of treatments, none of which has entered clinical trials yet. The companies did not say how much it is paying upfront.

The moves come six months after Pfizer said it would stop much of its work on early-stage gene therapy programs, in which researchers try to deliver replacement genes encased in small, non-pathogenic bugs called adeno-associated viruses, or AAVs. Instead, it would focus on newer technologies, such as gene editing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Why Titanic fascinates society, still drawing tours to the wreckage

leisure time

WSS

What AAP's gender

Florida group launches initiative to get abortion constitutional amendment on 2024 ballot

Complete sequence of Y chromosome published for first time

How redistricting in 6 states could affect who controls Congress

AstraZeneca challenges Medicare drug negotiation program

UPS workers' union leader explains what's at stake as strike edges closer

leisure time

hotspot

knowledge

Malaria cases in Florida and Texas: Here’s what you need to know

With fresh data, a dynamic duo powers Eli Lilly to new heights

Trump demands the U.S. pay no more for drugs than other countries … again

Study finds new variant for Parkinson’s in African populations

Heart attack and stroke risk calculators need revising

Florida group launches initiative to get abortion constitutional amendment on 2024 ballot

George Santos makes 1st court appearance after pleading not guilty to 13 counts

As pharma fights Medicare drug negotiation, hospitals, docs silent

Walensky prepares to leave CDC — and Congress — behind

AstraZeneca challenges Medicare drug negotiation program

focus

Florida group launches initiative to get abortion constitutional amendment on 2024 ballot

Australia’s approach to dialysis celebrates life

Neutralizing antibodies against HIV shows promise in children

In science, is the line between industry and academia shifting?

Departing Stanford president retracts two papers

Australia’s approach to dialysis celebrates life

hotspot

leisure time

hotspot

focus